WCM/EADO 2021 | Treating PD-1/PD-L1 refractory MCC
Paul Nghiem
• 14 Apr 2021
Paul Nghiem, MD, PhD, University of Washington, Seattle, WA, outlines ongoing trials for the treatment of refractory merkel cell carcinoma (MCC), including a Phase I/II trial of T-cell therapy of transgenic T-cell receptors (NCT03747484) and a trial of domatinostat. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
Disclosures
Paul Nghiem, MD, PhD, has served on an advisory board for EMD Serono and Pfizer and has received institutional research funding to institution from Bristol Myers Squibb and EMD Serono.
